With the continuous development of medical science and technology, research on cancer treatment has made significant breakthroughs. The iHuPBMC-OncVax model platform of InnoModels Biotechnology has attracted widespread attention. This vaccine platform has many unique features that bring new hope for cancer treatment.
Highly personalized:
The iHuPBMC-OncVax platform is prepared using the patient's immune cells, and personalized vaccines are tailored to the patient's specific situation. This highly personalized preparation can effectively improve the therapeutic effect of the vaccine on patients.
Dual Target Strike:
The iHuPBMC-OncVax vaccine platform employs two targets, which can ** both attack tumor cells by the immune system and inhibit the growth of tumor cells. This dual-target strike strategy can effectively improve the efficacy of the vaccine.

Innovative Preparation Process:
The iHuPBMC-OncVax vaccine platform employs an innovative preparation process that combines the patient's immune cells with tumor antigens to produce a vaccine that targets the patient's specific tumor. This process ensures a high degree of vaccine personalization and improves vaccine stability.
Wide range of application:
The iHuPBMC-OncVax vaccine platform is applicable to the treatment of a wide range of cancers, such as lung cancer, breast cancer and melanoma. This wide range of applicability makes this vaccine platform have a broad market prospect.
Remarkable clinical results:
According to the results of clinical trials, iHuPBMC-OncVax vaccine platform has achieved remarkable results in the treatment of various cancers. After using this vaccine, the condition of some patients has been effectively controlled and their survival period has been significantly extended.
In conclusion, iHuPBMC-OncVax is a breakthrough cancer vaccine platform from InnoModels Biotechnology, which brings new hope for cancer treatment with its highly personalized, dual-targeted strike, innovative preparation process, broad applicability and remarkable clinical efficacy. With further research and application of this vaccine platform, it is believed that more cancer patients will benefit.